Fisher Asset Management LLC Has $17.28 Million Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Fisher Asset Management LLC cut its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 9.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,884,097 shares of the biotechnology company’s stock after selling 301,102 shares during the quarter. Fisher Asset Management LLC owned 1.41% of BioCryst Pharmaceuticals worth $17,276,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Braidwell LP boosted its holdings in shares of BioCryst Pharmaceuticals by 92.1% during the third quarter. Braidwell LP now owns 5,362,980 shares of the biotechnology company’s stock worth $37,970,000 after purchasing an additional 2,571,100 shares during the period. Vanguard Group Inc. boosted its stake in shares of BioCryst Pharmaceuticals by 2.0% during the 3rd quarter. Vanguard Group Inc. now owns 15,392,319 shares of the biotechnology company’s stock valued at $108,978,000 after buying an additional 302,270 shares during the period. Jump Financial LLC boosted its stake in shares of BioCryst Pharmaceuticals by 371.5% during the 3rd quarter. Jump Financial LLC now owns 404,913 shares of the biotechnology company’s stock valued at $2,867,000 after buying an additional 319,037 shares during the period. Deerfield Management Company L.P. Series C grew its holdings in shares of BioCryst Pharmaceuticals by 148.6% during the 3rd quarter. Deerfield Management Company L.P. Series C now owns 3,286,000 shares of the biotechnology company’s stock valued at $23,265,000 after acquiring an additional 1,964,000 shares in the last quarter. Finally, Rice Hall James & Associates LLC increased its stake in shares of BioCryst Pharmaceuticals by 21.5% in the third quarter. Rice Hall James & Associates LLC now owns 2,275,638 shares of the biotechnology company’s stock worth $16,112,000 after acquiring an additional 402,674 shares during the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ BCRX opened at $4.45 on Monday. The firm has a market cap of $918.17 million, a price-to-earnings ratio of -3.77 and a beta of 1.96. The business’s 50-day simple moving average is $4.93 and its 200-day simple moving average is $5.46. BioCryst Pharmaceuticals, Inc. has a 52 week low of $4.03 and a 52 week high of $8.96.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Monday, February 26th. The biotechnology company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). The firm had revenue of $93.40 million during the quarter, compared to analyst estimates of $89.19 million. As a group, equities research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.69 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $12.00 price target on shares of BioCryst Pharmaceuticals in a research note on Wednesday, April 10th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $13.83.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.